BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition. Click here to ...
pharmaphorum3d
CSL preps filings for once-monthly antibody for HAE
If approved, garadicimab will slot into CSL's product line alongside two C1 esterase inhibitor medicines, namely Berinert which is administered by intravenous injection to treat HAE attacks ...
pharmaphorum5d
Phase 3 trial win sets up rare disease drug filing for CSL
If approved, garadicimab will slot into CSL’s product line alongside two C1 esterase inhibitor medicines, namely Berinert, which is administered by intravenous injection to treat HAE attacks ...
newsroom.csl6d
Swissmedic Approves CSL Behring’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ...